Trial Profile
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 24 Apr 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Therapeutic Use
- Acronyms COMMIT
- 20 Jan 2024 Trial design, presented at the 2024 Gastrointestinal Cancers Symposium
- 30 Mar 2023 Planned number of patients changed from 231 to 120.
- 07 Jun 2022 Trial design, presented at the 58th Annual Meeting of the American Society of Clinical Oncology